Health Care [ 3/12 ] | Biotechnology [ 26/74 ]
NASDAQ | Common Stock
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada.
Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy.
Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 6, 24 | -0.81 Decreased by -10.96% | -0.81 |
| Aug 8, 24 | -0.75 Decreased by -4.17% | -0.70 Decreased by -7.14% |
| May 9, 24 | -0.62 Increased by +1.59% | -0.66 Increased by +6.06% |
| Feb 29, 24 | -0.64 Decreased by -12.28% | -0.76 Increased by +15.79% |
| Nov 8, 23 | -0.73 Decreased by -28.07% | -0.77 Increased by +5.19% |
| Aug 9, 23 | -0.72 Decreased by -30.91% | -0.70 Decreased by -2.86% |
| May 9, 23 | -0.63 Decreased by -80.00% | -0.62 Decreased by -1.61% |
| Mar 1, 23 | -0.57 Decreased by -18.75% | -0.58 Increased by +1.72% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | N/A Decreased by N/A% | -62.79 M Decreased by -29.57% | - - |
| Jun 30, 24 | 0.00 Decreased by N/A% | -57.92 M Decreased by -22.05% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -47.93 M Decreased by -14.87% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 5.38 M Increased by +61.27 K% | -44.74 M Decreased by -19.65% | Decreased by -831.65% Increased by +99.81% |
| Sep 30, 23 | 0.00 Decreased by -100.00% | -48.46 M Decreased by -30.45% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by -100.00% | -47.46 M Decreased by -52.32% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by -100.00% | -41.73 M Decreased by -112.14% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 8.77 K Decreased by -99.77% | -37.40 M Decreased by -46.28% | Decreased by -426.59 K% Decreased by -62.26 K% |